Daprodustat

Research use only, not for human use.

A nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects.

A nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects; shows potential for the treatment of anemia associated with chronic kidney disease.Anemia Phase 3 Clinical(In Vitro):GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers.

GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers.

——

GSK-1278863 | GSK 1278863

Angiogenesis

HIF/HIF Prolyl-hydroxylase

HIF-PH

Other Indications

Anemia

960539-70-2

393.4342

C19H27N3O6

>98% (HPLC)

DMSO: < 6.8 mg/mL

O=C(O)CNC(C(C(N1C2CCCCC2)=O)C(N(C3CCCCC3)C1=O)=O)=O

Glycine, N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-

(-20℃)

With Ice Pack

≥ 2 years